CIK 0001671858 · Non-accelerated filer<br>Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811489190
- Phone
- 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −400 | 123,664 | ||
| 2025-02-03 | Shawver Laura Director | Option exercise 10b5-1 | +9,064 | $3.15 | $29K | 219,410 |
| 2025-02-03 | Shawver Laura Director | Option exercise 10b5-1 | +40,936 | $4.85 | $199K | 260,346 |
| 2025-02-03 | Shawver Laura Director | Sale 10b5-1 | −50,000 | $12.31 | $616K | 210,346 |
| 2025-02-03 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,064 | 0 | ||
| 2025-02-03 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,936 | 124,064 | ||
| 2025-01-06 | Shawver Laura Director | Option exercise 10b5-1 | +50,000 | $3.15 | $158K | 260,346 |
| 2025-01-06 | Shawver Laura Director | Sale 10b5-1 | −50,000 | $11.10 | $555K | 210,346 |
| 2025-01-06 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 9,064 | ||
| 2025-01-02 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Grant or award · Stock option (right to buy) | +261,900 | 261,900 | ||
| 2025-01-02 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +767,600 | 767,600 | ||
| 2025-01-02 | Lowenthal Richard E PRESIDENT AND CEO | Grant or award · Stock option (right to buy) | +767,600 | 767,600 | ||
| 2025-01-02 | Lowenthal Richard E PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +261,900 | 261,900 | ||
| 2025-01-02 | Fitzpatrick Alexander A Chief Legal Officer | Grant or award · Stock option (right to buy) | +152,300 | 152,300 | ||
| 2025-01-02 | Dorsey Brian Chief Operating Officer | Grant or award · Stock option (right to buy) | +261,900 | 261,900 | ||
| 2025-01-02 | Chakma Justin Chief Business Officer | Grant or award · Stock option (right to buy) | +274,100 | 274,100 | ||
| 2025-01-02 | Scott Kathleen D. Chief Financial Officer | Grant or award · Stock option (right to buy) | +176,700 | 176,700 | ||
| 2025-01-02 | Karas Eric Chief Commercial Officer | Grant or award · Stock option (right to buy) | +152,300 | 152,300 | ||
| 2024-12-17 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −50,000 | $11.67 | $584K | 1,297,447 |
| 2024-12-17 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale 10b5-1 | −50,000 | $11.67 | $584K | 1,098,499 |
Page 5 of 14 · 267 trades